Alpine Immune Sciences Dirección
Dirección controles de criterios 3/4
El CEO de Alpine Immune Sciences es Mitch Gold , nombrado en Jun 2016, tiene una permanencia de 7.92 años. compensación anual total es $2.92M, compuesta por 20.5% salario y 79.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.019% de las acciones de la empresa, por valor de $860.60K. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 6.1 años, respectivamente.
Información clave
Mitch Gold
Chief Executive Officer (CEO)
US$2.9m
Compensación total
| Porcentaje del salario del CEO | 20.5% |
| Permanencia del CEO | 7.9yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | US$3m | US$599k | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$3m | US$544k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$3m | US$523k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$1m | US$500k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$33m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$485k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$48m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$400k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$30m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$2m | US$300k | -US$8m |
Compensación vs. Mercado: La compensación total de Mitch($USD2.92M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.56M).
Compensación vs. Ingresos: La compensación de Mitch ha aumentado mientras la empresa no es rentable.
CEO
Mitch Gold (55 yo)
7.9yrs
Permanencia
US$2,921,224
Compensación
Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman & CEO | 7.9yrs | US$2.92m | 0.019% $ 860.6k | |
| President and Head of Research & Development | 5.1yrs | US$1.75m | 0.43% $ 19.2m | |
| Senior VP | 7.1yrs | US$1.28m | sin datos | |
| VP of Finance & Chief Accounting Officer | less than a year | sin datos | 0.044% $ 2.0m | |
| Chief Technology Officer | less than a year | sin datos | sin datos | |
| Director of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Chief Business Officer | 4.3yrs | sin datos | 0.15% $ 6.6m | |
| Chief Medical Officer | 1.8yrs | sin datos | sin datos |
4.3yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALPN se considera experimentado (4.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman & CEO | 9.3yrs | US$2.92m | 0.019% $ 860.6k | |
| Independent Director | 6.8yrs | US$110.21k | 0.073% $ 3.2m | |
| Independent Director | 7.9yrs | US$101.46k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$103.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$100.21k | 0% $ 0 | |
| Scientific Advisory Board Chairman | no data | sin datos | sin datos | |
| Independent Director | 6.1yrs | US$98.96k | 0.0028% $ 123.5k | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos |
6.1yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de ALPN se considera experimentada (6.1 años de antigüedad promedio).